Bullish
Eli Lilly's Mounjaro approved by FDA to reduce cardiovascular risk in type 2 diabetes patients.
Eli Lilly's diabetes drug, Mounjaro, has received FDA approval to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk. This approval is expected to significantly expand Mounjaro's market potential and revenue streams.
Key points
- FDA approval of Mounjaro to reduce cardiovascular risk in type 2 diabetes patients.
- No other significant news affecting Eli Lilly in the past 24 hours.
Sources
AI-generated from public news sources. Not financial advice.
